• ABT-263 (Navitoclax) for Apoptosis Assays

  2026-08-07

  ABT-263 (Navitoclax) converts Bcl-2-family dependence into a measurable mitochondrial apoptosis phenotype, supporting dose-response, priming, and combination studies. This workflow pairs the compound with orthogonal caspase and transcriptional-state measurements inspired by a 2025 Cell study while separating assay recommendations from product specifications.

• CB-5083 and p97 Inhibition: Unveiling New Frontiers in Prote

  2026-08-07

  Explore how CB-5083, a potent p97 inhibitor, advances the study of protein homeostasis disruption and cancer cell apoptosis induction. This article uniquely connects recent insights on stress granule dynamics and ER stress to CB-5083's practical application in oncology and neurodegeneration research.

• O-GlcNAcylation Enables Wnt-Induced Bone Formation via Glyco

  2026-08-06

  This study reveals that O-GlcNAcylation is essential for Wnt-driven bone formation, mechanistically linking Wnt signaling to glycolytic reprogramming in osteoblasts. By uncovering how Wnt3a-mediated O-GlcNAcylation of PDK1 stabilizes glycolytic flux, the work provides a critical metabolic perspective on osteogenesis with implications for bone disease therapies.

• Thymoquinone Mitigates Doxorubicin Cardiotoxicity via Nrf2/H

  2026-08-06

  This study provides the first direct evidence that thymoquinone, a bioactive quinone from Nigella sativa, protects against doxorubicin-induced cardiac injury in mice by activating the Nrf2/HO-1 pathway and reducing ferroptosis. The findings clarify the molecular mechanisms underlying thymoquinone's cardioprotective effects and offer concrete parameters for preclinical cardiac toxicity models.

• FXR-KLF11 Axis: CDCA Suppresses JAK2/STAT3 in AKI Models

  2026-08-05

  This study identifies the FXR-KLF11 axis as a key protective mechanism against contrast-induced acute kidney injury (CI-AKI). By activating FXR with CDCA, researchers demonstrated transcriptional upregulation of KLF11 and subsequent suppression of the JAK2/STAT3 pathway, providing mechanistic insight for future interventions in kidney injury and nuclear receptor signaling research.

• Amyloid β-Peptide (1-42): Ferroptosis, Ion Channels, and AD

  2026-08-05

  Explore the scientific basis of Amyloid β-Peptide (1-42) in Alzheimer's disease research, with a focus on ferroptosis, neuronal ion channel modulation, and assay design. This article uniquely connects mechanistic insights with cutting-edge findings for advanced laboratory applications.

• Thioguanine in Applied Research: Protocols and Troubleshooti

  2026-08-04

  Thioguanine (6-thioguanine) is a high-impact reagent for cancer, antiviral, and immunomodulatory studies—uniquely bridging DNA methyltransferase 1 inhibition and autophagy modulation. This article translates bench-proven workflows, troubleshooting tips, and latest comparative research into actionable protocols for advanced experimental design.

• Hepatic sEH–Nrf2 Axis Regulates Osteoclastogenesis in Osteop

  2026-08-04

  This study uncovers a novel liver-bone signaling axis in osteoporosis, showing that hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation by suppressing Nrf2 signaling, thereby contributing to redox imbalance and bone loss. These findings highlight the translational potential of sEH inhibitors for dissecting bone metabolism and inflammatory pathways in advanced disease models.

• Applied Workflows with Substance P: Optimizing Pain Transmis

  2026-08-03

  Substance P from APExBIO offers bench scientists a high-purity, reproducible tachykinin neuropeptide to dissect pain, inflammation, and immune pathways. This article translates emerging spectral interference solutions and hands-on assay troubleshooting into practical guidance, enabling robust, interference-free neurokinin signaling studies.

• Pepstatin A: Elevating Aspartic Protease Inhibition in Trans

  2026-08-03

  This thought-leadership article explores the mechanistic precision and translational impact of Pepstatin A as an aspartic protease inhibitor. Integrating recent mechanistic insights and protocol recommendations, it guides researchers through optimized experimental design for viral protein processing and osteoclast differentiation inhibition, while contextualizing APExBIO’s ultra-pure Pepstatin A as a new benchmark. The discussion bridges foundational enzymology with actionable translational strategies and offers a forward-looking perspective grounded in cutting-edge literature.

• A40926: Mechanistic Insights and Assay Optimization in Antib

  2026-08-02

  Discover the pivotal role of A40926, a dalbavancin precursor, in advancing antibacterial assay design and resistance research. This article delivers a unique, mechanistic perspective and actionable guidance for optimizing experimental protocols.

• DDI2-NFE2L1-UPS Axis Modulates Ferroptosis Sensitivity

  2026-08-01

  The reference study uncovers how the DDI2-mediated activation of NFE2L1 and the ubiquitin-proteasome system (UPS) provides critical protection against ferroptosis. By dissecting the molecular events linking proteasome regulation to ferroptotic cell death, the work highlights potential therapeutic strategies for sensitizing malignant cells to ferroptosis through targeted UPS modulation.

• Obeticholic Acid (6-ECDCA, INT-747) in Liver Fibrosis Resear

  2026-07-31

  This article delivers a scenario-driven, evidence-based exploration of Obeticholic Acid (6alpha-ethyl-chenodeoxycholic acid, 6-ECDCA, INT-747), SKU B4888, as a robust tool for liver fibrosis and hepatic inflammation models. Readers gain practical, literature-backed guidance optimized for reproducibility and assay performance. APExBIO’s offering stands out for its validated quality and workflow reliability.

• C34 TLR4 Inhibitor: Applied Workflows in Inflammatory Resear

  2026-07-31

  C34 is a selective TLR4 inhibitor that enables precise dissection of inflammatory signaling in macrophages and enterocytes. This article provides advanced workflow strategies, troubleshooting guidance, and real-world insights for robust application of C34 in both in vitro and in vivo models—bridging bench research to translational breakthroughs.

• AO/PI Double Staining Kit: Practical Cell Viability & Apopto

  2026-07-30

  The AO/PI Double Staining Kit enables rapid, multiplexed discrimination of live, apoptotic, and necrotic cells in research settings, supporting both fluorescence microscopy and flow cytometry. It is best suited for qualitative and semi-quantitative viability, apoptosis, and necrosis detection, but is not recommended for workflows requiring single-dye specificity or quantitative apoptosis kinetics.

764 records 8/51 page Previous Next First page 上5页 678910 下5页 Last page